HCL-PG03: Phase II Trial of Vemurafenib + Rituximab in Patients With Relapsed/Refractory Hairy Cell Leukemia

Slideset - A CR was achieved in 100% of patients with R/R HCL treated with the chemotherapy-free combination of vemurafenib plus rituximab.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research